NCT04586621

Brief Summary

The aim of this study is to evaluate the efficacy and safety of a new medical device (Atoldys/ Lexilens glasses) on the improvement of reading skills of young dyslexic subjects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
41

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 7, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 14, 2020

Completed
3 months until next milestone

Study Start

First participant enrolled

January 19, 2021

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 29, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 29, 2021

Completed
Last Updated

February 14, 2022

Status Verified

February 1, 2022

Enrollment Period

5 months

First QC Date

October 7, 2020

Last Update Submit

February 11, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Reading performance aloud of a text with french E.L.FE Test

    E.L.FE Test (=Evaluation de la Lecture en FluencE) - "Monsieur Petit" and "Le Géant égoïste" texts : percentile

    1 day

Secondary Outcomes (5)

  • Reading performance aloud of isolated words with french BALE Test

    1 day

  • Security: incidence of Adverse Events

    1 day

  • Security: device deficiencies

    1 day

  • Child's satisfaction regarding reading fluency and comprehension

    1 day

  • Speech therapist's satisfaction regarding Securirty, Performance and Usability of glasses

    1 day

Study Arms (2)

Atoldys/ Lexilens - SHAM

EXPERIMENTAL
Device: Atoldys/ Lexilens - SHAM

SHAM- Atoldys/ Lexilens

EXPERIMENTAL
Device: SHAM- Atoldys/ Lexilens

Interventions

Atoldys/ Lexilens: glasses with specific light frequency SHAM: glasses with no frequency

Atoldys/ Lexilens - SHAM

SHAM: glasses with no frequency Atoldys/ Lexilens: glasses with specific light frequency

SHAM- Atoldys/ Lexilens

Eligibility Criteria

Age8 Years - 13 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Schooled in CM1, CM2 or 6ème,
  • French mother tongue,
  • For whom developmental dyslexia has been diagnosed by a health professional who specializes in this learning disorder,
  • With near vision, without optical correction, equivalent to P5 or better according to the Parinaud scale (distance: 30-40 cm),
  • Presenting an IQ ≥ 80 and ≤130 according to the WISC-V test performed by a psychologist,
  • For whom a written consent was obtained regarding his study participation.

You may not qualify if:

  • With medical history or presenting a neurological pathology,
  • Presenting a developmental disorder (autism, ADHD, ...),
  • Presenting hearing disorders,
  • Presenting an astigmatism of more than one uncorrected diopter,
  • Presenting other visual disorders,
  • Any other condition that, in the opinion of health professionals, could impair its ability to complete the study or could pose a significant risk.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Dr Laurence Derieux

Caen, 14000, France

Location

Dr Luc-Marie Virlet

Faumont, 59310, France

Location

CHU Rennes

Rennes, 35000, France

Location

MeSH Terms

Conditions

Dyslexia

Condition Hierarchy (Ancestors)

Language DisordersCommunication DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSpecific Learning DisorderLearning DisabilitiesSigns and SymptomsPathological Conditions, Signs and SymptomsNeurodevelopmental DisordersMental Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 7, 2020

First Posted

October 14, 2020

Study Start

January 19, 2021

Primary Completion

June 29, 2021

Study Completion

June 29, 2021

Last Updated

February 14, 2022

Record last verified: 2022-02

Locations